Abstract:Cellular senescence is a major contributor to aging-related degenerative diseases, including Alzheimer's disease (AD) but much less is known on the key cell types and pathways driving mechanisms of senescence in the brain. We hypothesized that dysregulated cholesterol metabolism is central to cellular senescence in AD. We analyzed whole transcriptomic data and utilized single-cell RNA seq integration techniques to unveil the convoluted cell-type-specific and sub-cell-type-state-specific senescence pathologies in AD using both ROSMAP and Sea-AD datasets. We identified that microglia are central components to AD associated senescence phenotypes in ROSMAP snRNA-seq data (982,384 nuclei from postmortem prefrontal cortex of 239 AD and 188 non-AD) among non-neuron cell types. We identified that homeostatic, inflammatory, phagocytic, lipid processing and neuronal surveillance microglia states were associated with AD associated senescence in ROSMAP (152,459 microglia nuclei from six regions of brain tissue of 138 early AD, 79 late AD and 226 control subject) and in Sea-AD (82,486 microglia nuclei of 42 dementia, 42 no dementia and 5 reference subjects) via integrative analysis, which preserves the meaningful biological information of microglia cell states across the datasets. We assessed top senescence associated bioprocesses including mitochondrial, apoptosis, oxidative stress, ER stress, endosomes, and lysosomes systems. Specifically, we found that senescent microglia have altered cholesterol related bioprocesses and dysregulated cholesterol. We discovered three gene co-expression modules, which represent the specific cholesterol related senescence transcriptomic signatures in postmortem brains. To validate these findings, the activation of specific cholesterol associated senescence transcriptomic signatures was assessed using integrative analysis of snRNA-seq data from iMGs (microglia induced from iPSCs) exposed to myelin, Abeta, and synaptosomes (56,454 microglia across two replicates of untreated and four treated groups). In vivo cholesterol associated senescence transcriptomic signatures were preserved and altered after treatment with AD pathological substrates in iMGs. This study provides the first evidence that dysregulation of cholesterol metabolism in microglia is a major driver of senescence pathologies in AD. Targeting cholesterol pathways in senescent microglia is an attractive strategy to slow down AD progression.

Cholesterol Metabolism in Aging and Age-Related Disorders

Cholesterol metabolism in aging simultaneously altered in liver and nervous system

Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

Brain Cell Type-Specific Cholesterol Metabolism and Implications for Learning and Memory.

Cholesterol Metabolism and Homeostasis in the Brain

Exploring the Dynamic Changes of Brain Lipids, Lipid Rafts, and Lipid Droplets in Aging and Alzheimer's Disease

Central nervous system cholesterol metabolism in health and disease

Cholesterol metabolism in T‐cell aging: Accomplices or victims

Cholesterol imbalance and neurotransmission defects in neurodegeneration

Microglia States are Susceptible to Senescence and Cholesterol Dysregulation in Alzheimer's Disease

Implications of Sphingolipids on Aging and Age-Related Diseases

Cholesterol involvement in the pathogenesis of neurodegenerative diseases

Implication of Oxysterols and Phytosterols in Aging and Human Diseases

Lipids and Lipid Metabolism in Cellular Senescence: Emerging Targets for Age-Related Diseases

Changes in Cholesterol Metabolism in Peripheral Cells of Alzheimer Disease Patients and Their Relatives

Cholesterol metabolism regulates Tauopathy in Alzheimer's disease

Age-Related Changes in the Gut Microbiota Modify Brain Lipid Composition

The Role of Cholesterol Metabolism in Alzheimer’s Disease

Effects of aging on glucose and lipid metabolism in mice

Membrane Aging As the Real Culprit of Alzheimer’s Disease: Modification of a Hypothesis

Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development